120 related articles for article (PubMed ID: 33180422)
1. The Clinical Significance of Serum MASP-2 and IDH1 in the Early Diagnosis of Non-Small Cell Lung Cancer.
Chen Y; Wu ED; Ma S; Bai WQ; Yin YJ; Shi GL
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180422
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Sun N; Chen Z; Tan F; Zhang B; Yao R; Zhou C; Li J; Gao Y; Liu Z; Tan X; Zhou F; He MY; Shao K; Li N; Qiu B; Sun J; Yu Y; Wang S; Zhao Y; Shi X; He J
Clin Cancer Res; 2013 Sep; 19(18):5136-45. PubMed ID: 24046070
[TBL] [Abstract][Full Text] [Related]
3. The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients.
Zhang X; Ma S; Chen Y; Yin Y; Bai W; Tan J; Shi G
Int J Biol Markers; 2021 Dec; 36(4):27-35. PubMed ID: 34761718
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
5. Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial.
Sun N; Sun S; Gao Y; Li Y; Lu Z; Yuan Z; Che Y; Huang J; Mao S; Lei Y; Zang R; Li N; Cui W; Qi J; Chen F; Gao J; Wang J; Min R; Chen Y; Shi G; Tan F; He J
Cancer Sci; 2020 May; 111(5):1739-1749. PubMed ID: 32167618
[TBL] [Abstract][Full Text] [Related]
6. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
7. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
9. Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index.
Mishra A; Singh N; Shyam H; Jain M; Kumar Sahu D; Shankar P; Alam N; Kumar A; Jaiswal R; Kumar S
Gene; 2021 Jan; 766():145151. PubMed ID: 32950635
[TBL] [Abstract][Full Text] [Related]
10. [Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Xie H; Kong YX; Zhang Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):813-817. PubMed ID: 31907132
[No Abstract] [Full Text] [Related]
11. Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.
Lai Y; Wang Y; Wu Y; Wu M; Xing S; Xie Y; Chen S; Li X; Zhang A; He Y; Li H; Dai S; Wang J; Lin S; Bai Y; Du H; Liu W
Cancer Control; 2022; 29():10732748221104661. PubMed ID: 35653624
[TBL] [Abstract][Full Text] [Related]
12. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis value of the detection of CYFRA21-1 in non-small cell lung cancer].
GU J; WANG X; ZHAO H; ZHU S; WEN Y; XU H; LI L; CHEN J; ZHOU Q
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1118-21. PubMed ID: 21159246
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
15. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
Zhao H; Shi X; Liu J; Chen Z; Wang G
J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
[TBL] [Abstract][Full Text] [Related]
16. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
17. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
18. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
19. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
